Wed, Mar 4, 2015, 12:55 PM EST - U.S. Markets close in 3 hrs 5 mins


% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

  • buysell1929 buysell1929 Aug 1, 2013 8:10 AM Flag

    Earnings Released: Royalty Revenue Revised Up from $55 Million to $63 milliong for 2013

    Astex has revised its 2013 operational guidance for the following major items:

    Royalty revenue has been revised from $55 million to $63 million for 2013. The increase in royalty revenue is primarily driven by the delayed entry of generic competition after the expiration of market exclusivity for Dacogen in the U.S. on May 2, 2013. A competitor announced the launch of generic decitabine in the U.S. on July 12, 2013.
    Research and development expenses have been revised from $67 million to $70 million for 2013. The increase in research and development expenses is primarily influenced by the acceleration and/or revision of estimated costs associated with the Company's two priority programs SGI-110 and AT13387.
    The net loss estimated for 2013 has been reduced from the previous guidance of $30 million to a revised $25 million. Included in total operating expenses reflected in the revised annual net loss are approximately $12 million of non-cash charges.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
8.4950.0000(0.00%)Oct 10 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.